Halozyme Therapeutics Inc (HALO)
Receivables turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 1,015,324 | 947,355 | 873,304 | 862,989 | 829,253 | 780,710 | 773,653 | 704,980 | 660,116 | 580,623 | 487,477 | 471,567 | 443,310 | 463,010 | 412,496 | 331,262 | 267,594 | 199,556 | 180,470 | 164,397 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
December 31, 2024 calculation
Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,015,324K ÷ $—K
= —
The receivables turnover ratio for Halozyme Therapeutics Inc is not available for the period reported. A receivables turnover ratio measures how effectively a company is managing its accounts receivable by indicating how many times during a period the company collects its average accounts receivable balance. In the absence of this data, it is difficult to assess the efficiency of Halozyme Therapeutics Inc's receivables management and its impact on the company's cash flow and liquidity position. Therefore, it is advisable for the company to provide this key financial metric in future reporting to allow for a more comprehensive analysis of its financial performance and operational efficiency.
Peer comparison
Dec 31, 2024